Pretty good webcast. I wish Don provided more details on the IP/patent issues surrouding ZEN-003365. It sounds like another company had a similar molecule or a similar strategy or treatment of a similar indication, or a combination of these, filed in advance of the patent for ZEN003365, that led Zenith to believe that it would be a struggle to proceed with ZEN003365. Interesting that Don spoke of RVX-208 royalty stream comign to Zenith from the China deal, but the China deal isn't even finalized yet. I didn't hear Don comment on the pending nature of this deal. Kind of cool Don mentioned that they have a mini microarray to assess the efficacy of their anti-cancer inhibitors via a blood sample. Lots of good stuff in that web-cast. Don even mentioned a Nasdaq IPO that he is hoping happens by years end. Who gets to Nasdaq first.......Zenith or Resverlogix? Archived webcast is on the Zenith website on the newroom tab: http://www.zenithepigenetics.com/newsroom/presentations-&-publications.html